by admin-blog-kh | April 16, 2026 7:05 am
Obesity is a chronic disease, not a failure of willpower. For some people, nutrition changes, exercise, sleep correction and counselling are not enough on their own, especially when obesity is linked to diabetes, high blood pressure, fatty liver, sleep apnea or cardiovascular risk. India has now approved both semaglutide and tirzepatide for obesity or weight management. For obesity, semaglutide is marketed as Ozempic and Wegovy in India. Tirzepatide is marketed as Mounjaro, and Yurpeak is the second tirzepatide brand being distributed and promoted in India.
These medicines are not “slimming injections” for casual use. They are prescription therapies meant to be used as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity, or in adults who are overweight and also have at least one weight-related condition such as hypertension or type 2 diabetes. In other words, they are meant for medical weight management, not vanity weight loss.
Semaglutide is a GLP-1 receptor agonist. In simple terms, it mimics one of the gut hormones involved in appetite and blood sugar control. It acts on brain pathways linked to hunger and satiety, helps people feel fuller, reduces food cravings and calorie intake, and lowers blood sugar in a glucose-dependent manner by stimulating insulin and reducing glucagon when blood sugar is high. For obesity in India, semaglutide is available as Ozempic and Wegovy.
Tirzepatide is different. It is a dual GIP and GLP-1 receptor agonist. That means it targets two gut hormonal pathways instead of one. In practical terms, it improves glycaemic control, reduces appetite, increases satiety and fullness, lowers hunger, improves insulin sensitivity, lowers glucagon, and delays gastric emptying. This dual mechanism is the main reason many clinicians view tirzepatide as pharmacologically distinct from semaglutide, not just a higher-dose version of the same idea.
For weight management, tirzepatide is indicated for adults with obesity, or overweight adults with at least one weight-related comorbidity. In India, Mounjaro is Lilly’s brand, and Yurpeak is the second tirzepatide brand in the market.
The clearest difference is this: semaglutide targets GLP-1 alone, tirzepatide targets both GIP and GLP-1. Both are once-weekly injections, both reduce appetite, and both can support meaningful weight loss when combined with lifestyle change. But they are not identical in formulation, escalation schedule or biological action. Semaglutide for obesity in India is positioned around a build-up to 2.4 mg weekly. Tirzepatide uses a broader dose ladder, from 2.5 mg up to 15 mg weekly, and currently has both vial and pen presentations depending on the brand and product format.
For pregnant women, the answer is clear: these medicines are not recommended during pregnancy. The Indian Wegovy prescribing information says semaglutide should not be used during pregnancy and should be stopped if pregnancy occurs. Because semaglutide stays in the body for a long time, it should be discontinued at least 2 months before a planned pregnancy. Tirzepatide product information similarly advises against use in pregnancy and recommends stopping it at least 1 month before a planned pregnancy. Women of childbearing potential are advised to use contraception while on treatment.
In older adults, these drugs can be used, and neither semaglutide nor tirzepatide requires routine dose adjustment simply because of age. However, both product documents say experience in people aged 85 years and above is limited. In real-world practice, the bigger issue is not the calendar age alone, but frailty, reduced appetite, dehydration risk, kidney reserve, muscle loss and how well the person can tolerate nausea or vomiting. Tirzepatide guidance specifically notes that dehydration from gastrointestinal side effects can be especially relevant in the elderly.
For people living with type 2 diabetes, both medicines may be especially useful because they can help with both weight and blood sugar. But they need careful supervision. With semaglutide, the Indian prescribing information advises clinicians to consider reducing insulin or sulfonylurea doses when treatment is started, to reduce the risk of hypoglycaemia. Tirzepatide carries a similar warning, with the risk of hypoglycaemia rising when it is used alongside insulin or a sulfonylurea. This is why people with diabetes should never start these medicines on their own or based on social media advice.
There is another diabetes-related caution worth mentioning. Semaglutide’s safety profile includes diabetic retinopathy events in patients with type 2 diabetes, and tirzepatide advises caution in patients with proliferative diabetic retinopathy, diabetic macular oedema or retinopathy requiring acute treatment. So, if a person has diabetes and existing eye disease, the treating doctor should know before these drugs are prescribed.
For people with hypertension, these medicines are not automatically off-limits. In fact, hypertension is one of the weight-related comorbidities specifically listed in the obesity indications for semaglutide and tirzepatide. That does not mean either drug is a blood pressure medicine, but it does mean that as weight drops, blood pressure may improve, and some people may need their antihypertensive therapy reviewed rather than continued unchanged.
This is where the two drugs differ in a clinically important way. For semaglutide, the Indian Wegovy document says no dose adjustment is needed in mild or moderate renal impairment, but experience in severe renal impairment is limited and use is not recommended in severe renal impairment or end-stage renal disease. Tirzepatide is more permissive on paper, stating that no dose adjustment is required even in renal impairment including ESRD, though experience in severe renal impairment and ESRD is still limited and caution is advised. For both drugs, nausea, vomiting and diarrhoea can lead to dehydration, which in turn can worsen kidney function.
For liver disease, semaglutide again comes with more restriction. The Indian label says no dose adjustment is required in mild or moderate hepatic impairment, but semaglutide is not recommended in severe hepatic impairment. Tirzepatide states that no dose adjustment is required in hepatic impairment, though experience in severe hepatic impairment remains limited, so caution is still advised. In both situations, the presence of liver disease does not automatically rule treatment out, but it does mean a doctor should choose carefully and monitor the patient closely.
The most common side effects with both medicines are gastrointestinal, especially nausea, vomiting, diarrhoea and constipation. Semaglutide’s Indian prescribing information identifies these as the most frequently reported adverse reactions. Tirzepatide also commonly causes nausea, diarrhoea, vomiting, abdominal discomfort, constipation and dyspepsia, with gastrointestinal events becoming more frequent at higher doses. Both medicines can also be associated with gallbladder disease, pancreatitis warnings, delayed gastric emptying and, in people with diabetes on other glucose-lowering drugs, hypoglycaemia. This is why dose escalation, hydration and follow-up matter so much.
Any conversation about weight-loss drugs should now include childhood obesity, because India is seeing a clear and worrying rise. UNICEF India reported in 2025 that overweight and obesity are rising across all age groups, including children and adolescents. UNICEF also warned that India could be home to more than 27 million children and adolescents aged 5 to 19 living with obesity by 2030.
Indian paediatric experts have been raising the alarm for some time. The Indian Academy of Paediatrics guideline on childhood obesity notes that national data already show meaningful levels of overweight and obesity in children and adolescents, and that the burden has risen over time. The drivers are not mysterious: calorie-dense ultra-processed foods, sugary drinks, more screen time, less active play, urban food environments and family routines that make healthy choices harder than they should be. Childhood obesity is not just about appearance or school bullying. It increases the risk of long-term metabolic disease and often tracks into adulthood.
This is the part that needs the most care. These drugs should not be presented as routine prescriptions for children with excess weight. The Indian Wegovy prescribing information reviewed here frames semaglutide weight management as an adult indication and states that safety and efficacy are not established below 12 years. Tirzepatide product information says that for weight management, safety and efficacy are not established below 18 years. So, for childhood obesity in India, these medicines are not simple first-line options and certainly not medicines families should seek over the counter or through online shortcuts.
That said, the story is not as simple as “never.” Indian Academy of Paediatrics guidance says pharmacotherapy may be considered only as an adjunct to a comprehensive lifestyle program in selected adolescents aged 12 years and above, particularly those with class 2 obesity plus serious comorbidities, or class 3 obesity, when structured lifestyle treatment has not been enough. The same guideline discusses semaglutide as a GLP-1 option with adolescent obesity data. This means that paediatric obesity treatment can include medicines in carefully selected cases, but only under specialist supervision, with proper growth monitoring, nutrition support, psychological support and family-based behaviour change. It is not a cosmetic prescription, and it is not a shortcut.
One more nuance matters here. Tirzepatide product information does include paediatric dosing for type 2 diabetes in children aged 10 years and above in some jurisdictions, but that is a different indication from weight management. So when people hear that a drug “can be given to children,” they need to ask the next question: for what condition, at what age, and under whose supervision? For obesity alone, routine use in children is not where current Indian clinical practice should be heading.
Semaglutide and tirzepatide are important additions to obesity care in India, but they are not interchangeable, and they are not appropriate for everybody. Semaglutide is a GLP-1 receptor agonist marketed for obesity in India as Ozempic and Wegovy. Tirzepatide is a dual GIP and GLP-1 agonist marketed as Mounjaro, with Yurpeak as the second tirzepatide brand in India. Pregnancy is a clear no. Diabetes, hypertension, kidney disease, liver disease and advanced age require individualized assessment, not blanket approval or blanket rejection. And in children, any drug-based obesity treatment belongs firmly in specialist care, not in trend-driven prescribing.
Kauvery Hospital is globally known for its multidisciplinary services at all its Centers of Excellence, and for its comprehensive, Avant-Grade technology, especially in diagnostics and remedial care in heart diseases, transplantation, vascular and neurosciences medicine. Located in the heart of Trichy (Tennur, Royal Road and Alexandria Road (Cantonment), Chennai (Alwarpet, Radial Road & Vadapalani), Hosur, Salem, Tirunelveli and Bengaluru, the hospital also renders adult and paediatric trauma care.
Chennai Alwarpet – 044 4000 6000 • Chennai Radial Road – 044 6111 6111 • Chennai Vadapalani – 044 4000 6000 • Trichy – Cantonment – 0431 4077777 • Trichy – Heartcity – 0431 4077777 • Trichy – Tennur – 0431 4022555 • Maa Kauvery Trichy – 0431 4077777 • Kauvery Cancer Institute, Trichy – 0431 4077777 • Hosur – 04344 272727 • Salem – 0427 2677777 • Tirunelveli – 0462 4006000 • Bengaluru – 080 6801 68011
Source URL: https://www.kauveryhospital.com/blog/family-and-general-medicine/semaglutide-and-tirzepatide-are-now-approved-in-india-all-you-need-to-know-about-these-weight-loss-drugs/
Copyright ©2026 Kauvery Blog unless otherwise noted.